The primary type of HBV drug resistance testing we utilize is genotypic resistance testing, which involves sequencing the HBV polymerase gene to identify specific mutations known to confer resistance to nucleotide analogues (NAs) like lamivudine, adefovir, entecavir, and tenofovir. This molecular approach provides a direct and highly sensitive method to detect resistance-associated mutations, guiding personalized treatment strategies for patients.